Founded December 2011
Investors The Trendlines Group; private investors in Israel, United States, and Singapore; founders
CEO Ohad Schwartz
CoreBone has developed, and is distributing, bioactive, coral-based bone graft material that provides a natural alternative to human and animal-derived (bovine, porcine) bone grafts.
CoreBones patented technology embeds bioactive minerals (e.g., silicium) into the skeleton of corals during their growth process to accelerate healing and provide better connectivity. The CoreBone graft offers the same bonelike qualities as organic material (human/animal derived) without the associated risks.
CoreBone’s strictly controlled growing environment in its coral farm preserves the coral’s natural, bonelike properties.
CoreBone continues to expand sales. “We presented our products at the largest dental show in Cologne, Germany,” says CEO Ohad Schwartz, ” and received very positive feedback from visitors and distributors. Opinion leaders confirmed that the CoreBone material compares to the gold standard for dental bone graft. However, since we are not a bovine-derived product, our material is better replaced by bone (remodeling ) and appeals to segments (and countries) that are opposed to using human or animal derivatives.
“We are currently selling in France, Poland, Israel, and soon Romania, and have received distribution requests from other countries — and doctors — around the world. We signed a distribution agreement with a top dental implant company and give regular training sessions to customers and distributors. In this month alone, we are shipping 1,000 units.”
CoreBone earned CE mark and AMAR approval (from Israel’s Ministry of Health) to market its products in Israel and worldwide to the dental and orthopedic markets.
CEO Ohad Schwartz appears on Start-Up Stadium (Hebrew).
CoreBone's Ohad Schwartz interviewed on ILTV.
Ohad Schwartz presents at a Trendlines Showcase.
Former CEO, Vaica Medical (medication management); CEO and co-founder, Aspect AI (MRI technologies); VP, TAMI 4
Internationally recognized researcher in bone biology and dentistry; former head of Dental Dept. and Hard Tissue Laboratory, Sourasky Medical Center, Tel Aviv; School of Dental Medicine and Dept. of Bioengineering, Tel Aviv Univ.; senior researcher, Hospital for Special Surgery, New York
Today, implants are used more and more in dental and orthopedics. In many cases, bone is insufficient, and bone grafts stimulate the growth of new bone to support and anchor the implant. Most bone graft materials in the market are derived from human and animal bone and carry the risk of disease and rejection. *Furthermore, bovine-derived products hardly remodel due to the heat treatment that is essential to reduce viral risks. Synthetic materials, a fast-growing segment, lack strength.
Bone grafts from human and animal origin are in decline due to their associated risks. The synthetic bioactive product share is growing as the market seeks alternatives. The global market for orthopedic bone graft substitutes is expected to reach $3.4 billion by 2022 (Allied Market Research). According to Transparency Market Research, the global dental membrane and bone graft substitutes market is expected to reach $922.6 million by 2024.